This is due not only to lipid-lowering drugs and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, but also to the advent of intensive insulin therapy as a standard treatment for all patients with T1D following the results of the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study [5], as well as the use of advanced treatment options such as continuous infusion pumps, continuous glucose monitoring systems, new insulin analogues with better profiles and, more recently, hybrid closed-loop systems. This evidence concerns the gene INS and diabetes mellitus.